Cyteir Therapeutics, Inc. (CYT) News
Filter CYT News Items
CYT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CYT News Highlights
- For CYT, its 30 day story count is now at 6.
- Over the past 17 days, the trend for CYT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest CYT News From Around the Web
Below are the latest news stories about Cyteir Therapeutics Inc that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of DirectorsLEXINGTON, Mass., February 24, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Stephen Sands to its Board of Directors, to serve as a Class I director, effective as of February 22, 2022. Mr. Sands was also appointed to serve as a member of the Audit Committee. In connection with Mr. Sands’ appointment, the Board also increased the size of t |
Bargain Shopping? 3 “Strong Buy” Stocks That Are Down Over 50%Who doesn’t like a bargain? In these days, with price inflation hitting hard, we all want to find the best price on every purchase – and that includes our stock purchases. Bargain-conscious investors can still find those fundamentally solid stocks that are trading low; this is the essence of successful stock investing. To make it easy, we’ve done some of the background research. We’ve located three stocks that are down 50% or more, and confirmed that these are Strong Buy stocks, that have gotten plenty of recent approval from the Street’s stock pros. |
Cyteir begins dosing in phase 2 study of CYT-0851 to treat blood cancers, solid tumorsCyteir Therapeutics (NASDAQ:CYT) said the first patient was dosed in a phase 2 expansion cohort of a phase 1/2 trial of CYT-0851 being evaluated for treating hematologic malignancies and solid tumors. "This signal-seeking study in six different cancers will give us the data that may allow us to advance CYT-0851 into a... |
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851LEXINGTON, Mass., February 08, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors. |
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of DirectorsLEXINGTON, Mass., February 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John F. Thero to its board of directors. Mr. Thero will chair the audit committee. His appointment will increase the number of Cyteir board directors from eight to nine. |
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851LEXINGTON, Mass., January 12, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination with three standard-of-care chemotherapy regimens in both hematologic malignancies and solid tumors. |
Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceLEXINGTON, Mass., January 03, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022, at 2:15pm ET. |
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsLEXINGTON, Mass., December 16, 2021--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors. |
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business HighlightsLEXINGTON, Mass., November 12, 2021--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business highlights. |
Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare ConferenceLEXINGTON, Mass., November 01, 2021--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presentation at the Credit Suisse 30th Annual Healthcare Conference, being held virtually on November 8, 2021, at 4:20pm ET. |